Category: 3. Business

  • Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent’s Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

    • The collaboration combines Innovent’s proven immuno-oncology (“IO”) and antibody-drug conjugate (“ADC”) R&D capability and Takeda’s experience in global oncology drug development to accelerate Innovent’s two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program.
    • Innovent and Takeda will co-develop the IO backbone therapy IBI363 (PD-1/IL-2α-bias) globally and co-commercialize it in the U.S., where Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan; Takeda will receive exclusive commercialization rights outside Greater China and the U.S.
    • Innovent will grant Takeda exclusive rights for IBI343 (CLDN18.2 ADC) outside Greater China.
    • Innovent will grant Takeda an exclusive option for the rights for IBI3001 (EGFR/B7H3 ADC) outside Greater China.
    • Innovent will receive a US$1.2 billion upfront payment including a strategic equity investment of US$100 million at premium, and potential milestones for a total deal value of up to US$11.4 billion, and royalties.
    • Innovent to host conference calls and webcasts at 9:00 a.m. HKT (Chinese session) and 9:00 p.m. HKT (English session) on Wednesday, October 22, 2025.

    SAN FRANCISCO and SUZHOU, China, Oct. 21, 2025 /PRNewswire/ — Innovent Biologics (HKEX: 01801) announced a strategic global collaboration with Takeda (TSE:4502, NYSE:TAK) to advance next-generation IO and ADC cancer therapies, with the goal of developing potentially transformative cancer treatments to benefit patients worldwide.

    This partnership aims to leverage key synergies and accelerate the global development of several investigational medicines within Innovent’s IO+ADC pipeline, including: IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein demonstrating robust anti-tumor activity and potential to be a foundational next-generation IO therapy that is currently in Phase 3 clinical stage; IBI343, a potentially best-in-class CLDN18.2 ADC currently in Phase 3 clinical stage; and IBI3001, a first-in-class EGFR/B7H3 bispecific ADC currently in Phase 1 clinical stage.

    Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent Biologics, stated, 

    “We believe that developing innovative IO and ADC will be a key direction for redefining cancer treatment worldwide. This landmark collaboration with Takeda brings together our three next-generation assets. With clear, aligned development plans, Innovent’s deep understanding of these assets, combined with Takeda’s extensive experience and strong development and commercialization capabilities, we are committed to delivering these promising medicines to patients worldwide as quickly as possible. This collaboration is also a crucial step in fulfilling Innovent’s strategic roadmap as we expand our global footprint, with the goal of becoming a leading global biopharmaceutical company.”

    “We are excited to partner with Innovent, an accomplished team with deep expertise in next-generation immuno-oncology and ADC biology,” said Teresa Bitetti, President of the Global Oncology Business Unit at Takeda.  “IBI363 and IBI343, two next-generation investigational medicines, have the potential to address critical treatment gaps for patients with a range of solid tumors. We are energized by the progress made by Innovent  to date and look forward to collaborating to unlock the potential of these programs. Our global research and development expertise  and commercialization capabilities will enable us to accelerate the delivery of these investigational medicines to patients. These two programs have the potential to be transformative for our oncology portfolio and significantly enhance Takeda’s growth potential post-2030.”

    IBI363 (PD-1/IL-2α-bias): Global Joint Development and Commercialization Collaboration

    IBI363, developed by Innovent Biologics, is a potentially first-in-class PD-1/IL-2α-biased bispecific antibody fusion protein that simultaneously blocks the PD-1/PD-L1 pathway and activates the IL-2 pathway. Innovent has shown that IBI363, with an IL-2 receptor alpha focused approach, selectively expands tumor-specific CD8+ T cells that increase tumor cell killing efficiency without activating or expanding the toxicity related to peripheral T cells, which results in a better safety profile than what is seen with traditional IL-2s. Phase 1b/2 results presented at ASCO 2025 have demonstrated outstanding tumor responses and preliminary survival benefits of IBI363 across immunotherapy-resistant lung cancer, “cold tumors” such as acral and mucosal melanoma, and MSS colorectal cancer. IBI363 is now in registrational clinical development, including a global Phase 3 study in second line sqNSCLC that is expected to begin in the coming months; the China NMPA has granted Breakthrough Designation (BTD) and U.S. FDA has granted Fast Track Designation (FTD) for this indication.

    According to the agreement, Innovent and Takeda will co-develop IBI363 globally, sharing development costs 40/60 (Innovent/Takeda). In the U.S., Innovent and Takeda will co-commercialize IBI363, sharing the U.S. profit or loss 40/60. Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan. In addition, Innovent will grant Takeda commercialization rights outside Greater China and the U.S. Takeda will have global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S. Takeda will pay Innovent potential development and sales milestones outside Greater China, and tiered royalties up to high-teens on net sales outside Greater China and the U.S.

    This collaboration aims to explore and maximize IBI363’s potential as a new IO backbone therapy through aligned co-development plans. Building on its already robust clinical data of over 1,200 treated patients, IBI363 will be initially developed globally in non-small cell lung cancer (“NSCLC”) and colorectal cancer (“CRC”), including in the first-line settings. Additionally, Takeda and Innovent plan to expand IBI363’s clinical development to additional indications.

    IBI343 (CLDN18.2 ADC): Global License for Development and Commercialization

    IBI343, developed by Innovent Biologics, is an innovative TOPO1 inhibitor ADC targeting CLDN18.2. Clinical data show a favorable safety profile and encouraging efficacy signals. It is currently being evaluated in a Phase 3 clinical trial in gastric/gastroesophageal cancers (G-HOPE-001) in China and Japan, and was granted Breakthrough Designation in China. IBI343 also completed a global Phase 1/2 trial in previously treated pancreatic ductal adenocarcinoma (PDAC) and has received Breakthrough Designation in China for this indication. It has also received Fast Track Designation from the U.S. FDA for the treatment of advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) that has relapsed and/or is refractory to one prior line of therapy.

    Innovent will grant Takeda exclusive global rights to develop, manufacture and commercialize IBI343 outside of Greater China. Takeda plans to advance the development of IBI343 and expand into first-line gastric and pancreatic cancer settings.

    Takeda will make potential milestone payments, and tiered royalties on net sales up to high-teens for the license of IBI343.

    IBI3001 (EGFR/B7H3 ADC): Option to Global License for Development and Commercialization

    IBI3001, currently in a Phase 1 clinical trial, is a first-in-class bispecific ADC targeting B7-H3 and EGFR. It combines multiple anti-tumor mechanisms, including enhanced EGFR blockade, receptor-mediated internalization, and strong ADC-mediated cytotoxicity, with a high safety margin demonstrated in preclinical models.

    Innovent will grant Takeda an exclusive option to license global development, manufacturing, and commercialization rights for IBI3001 outside of Greater China. If exercised, Takeda will pay Innovent an exercise fee, potential milestone payments, and tiered royalties on net sales up to mid-teens.

    Financial Highlights: Total Deal Value up to $11.4Billion

    Takeda will pay Innovent an upfront payment of US$1.2 billion, including a US$100 million equity investment in Innovent through new share issuance, at HK$112.56 per share, a 20% premium to the Innovent 30-trading-day weighted average share price.

    Furthermore, Innovent is eligible for development and sales milestone payments for IBI363, IBI343, and IBI3001 (if option exercised) totaling up to approximately $10.2 billion, for a total deal value of up to $11.4 billion. Innovent will also receive potential royalty payments for each molecule outside Greater China, except with respect to IBI363 in the U.S., where the parties will share profits or losses.

    Innovent will host conference calls and webcasts at 9:00 a.m. HKT (Chinese session) and 9:00 p.m. HKT (English session) on Wednesday, October 22, 2025.Details of the conference call dial-in and the webcast link will be provided on the company website at https://investor.innoventbio.com/en/investors/webcasts-and-presentations/. A replay will also be available on the website shortly after the event.

    Morgan Stanley Asia Limited serves as the exclusive financial advisor to Innovent Biologics in relation to this transaction.

    About Innovent Biologics

    Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

    Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

    Statement:  Innovent does not recommend the use of any unapproved drug (s)/indication (s).

    Forward-looking statement of Innovent Biologics

    This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

    These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

    Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

    SOURCE Innovent Biologics

    Continue Reading

  • Our brains evaluate food within milliseconds, long before we’ve decided to eat it

    Our brains evaluate food within milliseconds, long before we’ve decided to eat it

    Imagine you’re at the grocery store, standing before a selection of snacks. Seemingly without thinking, you skip over the rice crackers to pick out a bag of chips.

    These types of choices are called dietary decisions. It’s how we consider many different aspects of a food – including tastiness, healthiness and price – in order to decide what to buy and what to eat.

    It’s not well understood how our brains use all these different bits of information when making food choices. When does information about each aspect of the food become available to our brains to consider? That’s what we set out to investigate.

    In our new paper published in the journal Appetite, we show how, just hundreds of milliseconds after we have seen a food, many different attributes are reflected in brain activity. This happens extremely fast, long before a person can consciously decide whether or not to buy or eat the food.

    Peering inside the brain

    Naturally, how fast our brains process the different aspects of foods will affect our dietary decisions.

    For example, studies have reported that we may process how tasty we find a food more quickly than how healthy it is. This quirk can bias our choices toward foods that taste better over those that are healthier. Junk foods – tasty but not necessarily good for us – have an edge here.

    To investigate how quickly we process different aspects of foods, we used electroencephalography, a method that allows us to record electrical brain activity with millisecond precision.

    We recorded people’s brain activity while showing them images of various foods, such as snack items, meats, fruits and sweets. We also asked people to rate each food on many different aspects, such as healthiness, tastiness, calorie content, familiarity, and how much they would like to eat the food.

    An example of a food item presented in the study.
    Chae et al., 2025

    We then used machine learning techniques to compare patterns of brain activity (how different the brain responses were to different food items) with the patterns of ratings (how differently those foods were rated).

    This allowed us to test whether foods that had the largest differences in ratings also had the largest differences in brain activity. In other words – was information about food attributes actually reflected in people’s brain activity?

    As it turned out, it was.

    Information about different aspects of foods, such as healthiness, calorie content and familiarity, were reflected in the brain activity as early as 200 milliseconds after the food image was presented on the screen.

    These rapid brain responses occurred before people could be consciously aware of the food they were seeing. Other aspects of foods, such as tastiness and willingness to eat the food, were reflected in the brain activity slightly later.

    Choosing before choosing

    These findings suggest that various aspects of foods may grab our attention early and help guide our dietary decisions. The brain assesses many different aspects of foods automatically and with similar timing, shaping our food choices before we’re even aware of them.

    Surprisingly, we found that the healthiness of foods was represented in the brain activity earlier than tastiness. While this contradicted some previous findings, our machine learning techniques may have been more sensitive to detect subtle patterns of brain activity associated with each attribute.

    There were also similarities in the way people judged different aspects of a food. For example, foods that were less familiar were also rated as being less tasty.

    From these patterns of similarity, we identified two key food dimensions that may be particularly important when our brains evaluate foods. The first one is the “processed” dimension: how natural or processed a food is. The second is the “appetising” dimension, which taps into how tasty and familiar we find a food.

    Both were reflected in patterns of brain activity very rapidly, about 200ms after seeing a food item.

    There’s more than the eye can see

    Our findings are most relevant to situations where we only rely on the visual features of foods, such as when ordering groceries or meals online, or using a picture menu at a restaurant. They shed light on how people make snap judgements at the supermarket or on food delivery apps.

    Our brain imaging approach can also be used to test if certain strategies, such as deliberately focusing on the healthiness of foods, might change how foods are rapidly appraised and help us improve our choices.

    While we used food images in this study, other senses are also important for dietary decisions. Smelling a mango or hearing the sizzle of a frying burger patty are likely processed quickly by the brain as well.

    The next step will be to look into these other sensory features of foods, to see how the brain processes not just images of food, but the real deal when placed in front of us.

    Continue Reading

  • Sustainable Aviation Fuel: Opportunities for Hong Kong

    Sustainable Aviation Fuel: Opportunities for Hong Kong

    Hong Kong is eyeing sustainable aviation fuel (SAF) as it races to achieve carbon neutrality before 2050.

    Airplane travel is one of the most carbon-intensive activities. In 2023, the aviation industry’s carbon emissions reached 950 megatonnes, accounting for 2.5% of the world’s emissions. To address this issue, sustainable aviation fuel (SAF) has been developed as an alternative to petroleum-based aviation fuel. 

    As announced in the Hong Kong Policy Address 2025, Hong Kong is eyeing SAF. In this respect, the city is planning to develop a SAF industry chain in cooperation with mainland China authorities, adopt specified SAF consumption targets for flights departing from the Hong Kong International Airport by 2030, and build a SAF blending facility to boost competitiveness.

    What Is SAF?

    Instead of petroleum, SAF is made from sustainable feedstock such as municipal solid waste, agricultural residues, oils, and fats.

    The Fischer-Tropsch Synthetic Paraffinic Kerosene is one of the most common types of  SAF. First, the appropriate feedstock, like wood waste, agricultural residue, and municipal solid waste, will undergo a thermochemical process called gasification. During this process, biomass will first be heated to remove its water content and break its structure into simpler molecules. Then, a chain of chemical reactions will happen under high temperature (above 700) in an environment with limited oxygen. As a result, the biomass will be converted into syngas that primarily consists of carbon monoxide and hydrogen. After removing the impurities, the syngas can be fed into the reactor to produce liquid hydrocarbons by undergoing the catalytic chemical reaction. The liquid hydrocarbons can be used as aviation fuel after refining.

    Why SAF?

    There are various advantages to adopting SAF in Hong Kong. 

    First, SAF is a drop-in fuel that can be directly used in current aircraft. It means that there is no impact on the performance, and no modification or extra infrastructure is required. 

    Depending on the type of feedstock and production methods, SAF can be blended with conventional aviation fuel in a range of 10% to 50%, with lifecycle carbon emission reductions of up to 80% compared with conventional fuel. Using SAF can also improve air quality by lowering emissions of sulfur and particulate matter.

    All this makes SAF a great ally in decarbonization efforts globally and in Hong Kong – the city is committed to reducing carbon emissions by 50% compared with the 2005 level by 2035 and achieving carbon neutrality by 2050. 

    Commercial airplanes at the Hong Kong International Airport. Photo: Jeffry S.S. via Pexels.

    Developing SAF is also beneficial for businesses. While airlines can reduce the scope one emissions generated by their aircrafts, other companies can also benefit in the resulting reduction of upstream scope three emissions generated by business travel. As a result, these companies can not only lower their carbon footprint but also reduce the risk of financial loss caused by climate change. 

    As required by the Hong Kong Exchange and Clearing Limited, all listed companies in Hong Kong have an obligation to disclose sustainability-related information – better known as Environmental, Social, and Governance (ESG) standards – to the public. Therefore, companies that develop or support SAF can increase their business reputation and attract new investment.

    Challenges

    Although developing SAF is a good solution to decarbonize aviation, it comes with some challenges. 

    Currently, the cost of SAF is about two to three times that of conventional aviation fuel. The reason is associated with the limited feedstock supply. Some feedstock, such as crop and virgin oil-based feedstock, may lead to deforestation, land use change, and biodiversity loss. If forests are removed, a massive amount of carbon dioxide stored in the trees will be released back to the atmosphere. 

    It is also difficult to ensure a consistent supply of feedstocks like solid waste and agricultural residues. This, in turn, means higher production costs. As a result, airlines may continue to use conventional aviation fuel to save costs and avoid increasing ticket prices. 

    Overcoming these challenges requires detailed planning and supportive policies, such as diversified feedstock and production methods and government subsidies. 

    Moreover, global SAF adoption is slow. In 2024, global SAF production accounted for just 0.3% of the total aviation fuel production. It is expected to reach 0.7% of total jet fuel production this year.

    Without government incentives and leadership, research and development as well as adoption of SAF technology will lag behind, hindering progress of the aviation industry’s decarbonization efforts.

    More on the topic: Sustainable Aviation Fuel: State of the Industry and Challenges

    Greenwashing Accusations

    SAF has been described as a form of greenwashing – when companies make misleading statements about the environmental impacts of their products as a marketing tactic.

    In fact, SAF is a vague term. People with an inadequate understanding may think it is a completely sustainable solution that has zero emissions. Unfortunately, that is far from the truth. During the combustion of jet engines, carbon dioxide will still be released into the atmosphere, even though the lifecycle carbon emissions of SAF are significantly lower. At the same time, air pollutants such as nitrogen oxides, sulfur oxides, carbon monoxide, and particulate matter will still be emitted, impacting air quality.

    Global Trends

    Despite slow adoption, multiple countries have implemented rules requiring aviation fuel suppliers to increase blending of SAF with conventional aviation fuel. For example, the United Kingdom introduced a SAF Mandate earlier this year. The requirement will increase linearly, from 2% in 2025 to 10% in 2030 and 22% in 2040. In the European Union, the ReFuelEU Aviation measure requires a share of SAF in EU airports from this year, which will gradually increase to 70% by 2050. Both mandates have excluded crop and virgin oil-based feedstocks to avoid deforestation, land use changes, and biodiversity loss.

    Brazil, the host country of this year’s UN climate change summit, COP30, launched the Belém Commitment for Sustainable Fuels. Announced last week, the initiative aims to quadruple the production and use of sustainable fuels in aviation by 2035. The proposal has won the support from India, Italy, and Japan, and it will be presented at the climate conference in Belém next month.

    Scaling Up SAF in Hong Kong

    Although Hong Kong does not require airlines to use SAF, Hong Kong-based airline Cathay Pacific has already implemented Asia’s first major SAF program. Launched in 2022, it commits the company to incorporate SAF for 10% of its total fuel consumption by the end of the decade. On October 21, the airline announced a joint investment agreement with Airbus, committing to co-invest up to US$70 million to support the SAF development in Asia and globally.

    Under the terms of the partnership, the two companies will work to identify,”evaluate and invest in projects that support the scaling of SAF production towards 2030 and beyond. Projects will be assessed based on their commercial viability, technological maturity, and potential for long-term offtake,” a press release read.

    Among the Cathay Pacific SAF program’s partners is Hong Kong’s Airport Authority (AAHK). Its General Manager for Sustainability, Peter Lee, said: “We recognise that SAF is a key solution to decarbonise the aviation sector, and aim to drive uptake at Hong Kong International Airport in the coming years.”

    A Cathay Pacific plane approaching the Hong Kong International Airport.
    A Cathay Pacific plane approaching the Hong Kong International Airport. Photo: Wikimedia Commons.

    As an international logistics hub, the Hong Kong International Airport has been the world’s busiest international cargo airport since 2010. In 2024, it handled about five million tonnes of cargo and 54.9 million passengers. With such a high flow, it is crucial to develop SAF policy and facilities to demonstrate Hong Kong’s commitment to achieving carbon neutrality and enhancing its global competitiveness and reputation.

    Speaking at a conference last October, Cathay’s General Manager of Sustainability Grace Cheung called for more government pressure for Hong Kong’s aviation sector to meet its climate goals.

    “Regulators have a key role to play for a level playing field, so that every [player] is doing the right thing for society,” Cheung said, according to the South China Morning Post. “If we leave it to the market, every company will wait for their competitors to make the first move.”

    As Hong Kong plans to develop a SAF industry chain and build a SAF blending facility, the production technology will improve and become more cost-effective in the long run. When that happens, airlines will have more incentive to use SAF.

    Continue Reading

  • Japan September exports rebound, after four straight months of declines

    Japan September exports rebound, after four straight months of declines

    YOKOHAMA, KANAGAWA, JAPAN – 2025/08/28: A loaded container ship is docked inside Tokyo Bay.

    Sopa Images | Lightrocket | Getty Images

    Japanese exports in September snapped four months of declines, climbing 4.2% year on year, as shipments to Asia saw robust growth, partially offsetting the drop in exports to the U.S.

    Exports, however, missed expectations of a 4.6% rise, according to median estimates in a Reuters poll of economists.

    Shipments to Asia climbed 9.2% compared to the same period last year, while exports to the U.S., Japan’s second largest trading partner, dropped 13.3%. Exports to mainland China, Japan’s largest trading partner rose 5.8%.

    Japan’s exports had fallen into negative territory as the country grappled with U.S. tariffs with its shipments of automobiles to the world’s largest economy taking a huge hit.

    Auto shipments to the U.S. dropped 24.2% in September in terms of value, a softer fall compared to the 28.4% drop in August.

    The world’s fourth-largest economy saw imports increase 3.3% year on year, reversing course from the 5.2% decline in August and beating the 0.6% growth expected by the Reuters poll.

    Tokyo in July clinched a trade deal with Washington, bringing down tariffs on its exports to the U.S. to 15% from the 25% initially proposed by President Donald Trump.

    The data comes a day after the country got its first female prime minister in Sanae Takaichi, after months of political turmoil following electoral losses of the ruling Liberal Democratic Party under former Prime Minister Shigeru Ishiba.

    Takaichi’s stance of a loose momentary policy and massive fiscal stimulus is likely to weaken the yen, making Japan’s exports more competitive and benefiting exporters — heavyweights on the benchmark Nikkei 225 that hit a record high on Tuesday.

    Markets have priced in the so-called “Takaichi trade” since she took the helm of the LDP in September, which has seen the Nikkei rise to record highs and the yen weakening past the 150 mark.

    However, the country’s economy has held up better than expected, with the second-quarter GDP being revised upward to 0.5% quarter on quarter from 0.3% estimated initially.

    Continue Reading

  • What’s likely to move the market in the next trading session

    What’s likely to move the market in the next trading session

    Continue Reading

  • Asia-Pacific stocks mixed as Japan ushers in new leadership

    Asia-Pacific stocks mixed as Japan ushers in new leadership

    Mount Fuji and the Shinjuku skyline in Tokyo, Japan, on Friday, Feb. 14, 2025. Photographer: Kiyoshi Ota/Bloomberg via Getty Images

    Bloomberg | Bloomberg | Getty Images

    Asia-Pacific markets fell Wednesday as investors assessed trade data from Japan and its new government.

    Japanese exports in September snapped four months of declines, climbing 4.2% year on year, as shipments to Asia saw robust growth, partially offsetting the drop in exports to the U.S.

    Exports, however, missed analysts’ expectations of a 4.6% rise, according to median estimates in a Reuters poll of economists.

    Prime Minister Sanae Takaichi and her new cabinet were sworn in on Tuesday, with her former rival in the ruling Liberal Democratic Party’s leadership race, Shinjiro Koizumi, named defense minister and Satsuki Katayama becoming Japan’s first female finance minister.

    Japan’s Nikkei 225 was down 1.26%, leading losses in Asia, while the Topix index lost 0.18%. Shares of SoftBank plunged over 10%, building on their 0.26% drop on Tuesday. Shares had gained 8.5% on Monday.

    On Tuesday, the Nikkei briefly set a new intraday record of 49,945.95, before retreating after Takaichi won the parliamentary vote to become Prime Minister.

    South Korea’s Kospi index was down 0.26%, while the small-cap Kosdaq fell 0.25%. Shares of LG Chem soared as much as 10% after Palliser Capital urged the chemicals company to revamp its board and buy back shares, according to a Reuters report.

    Australia’s S&P/ASX 200 started the day down 0.73%, pulling back from earlier gains on Tuesday after rare earth stocks briefly rallied on news of a U.S.-Australia critical minerals agreement.

    Hong Kong Hang Seng index futures were at 25,919, lower than the last close of 26,027.55.

    Indian markets are closed for a holiday.

    Overnight in the U.S., the Dow Jones Industrial Average set a new closing record, boosted by strong earnings reports from companies such as Coca-Cola and 3M, while the S&P 500 was relatively unchanged.

    The 30-stock index gained 0.47% to close at 46,924.74, and briefly topped 47,000 during the session.

    The broad market S&P 500 closed just above the flatline at 6,735.35, while the tech-heavy Nasdaq Composite lagged, falling 0.16% to 22,953.67.

    —CNBC’s Sean Conlon and Pia Singh contributed to this report.

    Continue Reading

  • Why supermarket prices really became sky high in the UK

    Why supermarket prices really became sky high in the UK

    Faisal Islam profile imageFaisal IslamEconomics editor

    BBC A treated image showing several glasses of orange juice on a colorful background
BBC

    There has been more than a bitter twang in the glasses at British breakfast tables. Only five years ago, a typical supermarket own-label carton of orange juice could be bought for 76p for 1 litre. It now costs £1.79.

    That’s a rise of 134% since 2020, and it’s up 29% just in the past year.

    In cafes and restaurants it’s a similar story – with £3.50 to £4 now a standard price point for a glass of basic OJ.

    One colleague was outraged to be sent a bill for £9 for a glass of hangover-busting orange juice and lemonade at an unassuming little restaurant in Kent. Asked why so much, she was told that the orange juice – albeit freshly squeezed – accounted for £5.30 of the price.

    Yet as costs have surged, the taste is changing too, with certain manufacturers substituting oranges for mandarins to cut costs.

    The public is, if you like, being freshly squeezed.

    A chart showing how some orange juice prices have increased. For example, in October 2020 an own label ambient smooth juice was £0.76 and in October 2025 was £1.79 - marking a 134% increase

    There are all sorts of reasons for this: disease among crops, extreme weather, over-reliance on supply from a single nation, new rules for packaging and complexities around trade wars and Brexit.

    All of this is compounded by grocery price inflation which, after hitting 17.5% in 2023, came down (to around 5.7% in August) but is rising once again. New figures for overall inflation will be released later today.

    It is a perfect storm.

    Yet the problem is not isolated to orange juice – track the prices of all sorts of other groceries in supermarket aisles and you’ll see a similar pattern. And so understanding what has happened to orange juice offers a glimpse into how our overall grocery bills suddenly seem so expensive.

    It all prompts the question: is this storm a passing one, or are prices set to remain stubbornly high – and should brace for them staying that way permanently?

    The Bing Crosby effect

    Where else to start but in the orange groves of Florida where the industrialisation of OJ began as an initiative of the US Army during World War Two.

    The US government was seeking a source of transportable Vitamin C for troops that didn’t taste like turpentine.

    Hulton Archive/Getty Images Full-length portrait of Marilyn Crane posing with Minute Maid's 'Mechanical Man' made from aluminum cans of orange juice 
Hulton Archive/Getty Images

    Orange juice from concentrate was commercialised by Minute Maid

    Orange juice is nearly 90% water. So gently evaporating the water off the juice and freezing the concentrate, allowed for transportability of a much better tasting product when water was later re-added.

    WW2 ended before the troops got to try it, but it ended up being commercialised by what became the American soft drink giant, Minute Maid.

    It was popularised by Bing Crosby, who, as a significant shareholder, would sing in ads and radio show jingles about frozen orange juice being “better for your health”.

    Western consumption of orange juice surged.

    TV Times/ Getty Images/ Screen Archives A dual image showing Bing Crosby dressed as Santa Claus on the set of his holiday special Bing Crosby's White Christmas (left) and Bing as he poses in an armchair (right)
TV Times/ Getty Images/ Screen Archives

    Minute Maid orange juice was popularised by Bing Crosby

    Flash forward to today and an estimated 2.5 billion gallons of orange juice are drunk each year – with about a tenth of that in the UK, where the market is still growing.

    Drought, disease and flooding

    At an industrial unit in the Essex town of Basildon, green steel drums of frozen orange concentrate arrive from Brazil, overseen by Maxim McDonald.

    His firm Gerald McDonald and Co is named after his grandfather, a pioneer who was importing orange concentrate as far back as the 1940s from what was then British-mandate Palestine.

    Today it produces juices and blends them, then sells them to supermarkets and restaurant suppliers.

    But prices reached extraordinary heights in global markets, rising from $1(75p) to $1.50 (£1.12) per lb over the last decade, to a record $5.30 per lb by the end of last year.

    This followed five years of poor crops, owing to severe drought and a disease called citrus greening (caused by a bacteria spread by insects). Brazil had its worst crop since 1988. In some parts of its citrus belt, two thirds of orange trees are affected.

    “Around September of last year the price shot up to crazy levels,” Maxim tells me. “At the worst time I was being offered $7 a kilo.

    “For such a major commodity to go from $2 to $7 is insane, but it took a while to filter through to consumers.”

    Until 2023 the rise in orange juice prices was disguised among food inflation in general, explains Philip Coverdale, an industry expert at consultancy firm GlobalData.

    Producers have tried to look beyond South America but it’s not easy – the supply of oranges has been sown up by Brazil, even more so than, say, the Saudis have cornered the market for crude oil.

    Morocco, Egypt and South Africa grow oranges too but their supplies are more limited. Spain also grows them, but Valencia and Seville oranges are mostly exported as fruit, rather than concentrate. (Plus Spain too suffered from weather-related production slumps, including the floods in Valencia last October.)

    AFP via Getty Images A man recovers oranges from a tree, with the ground flooded below


AFP via Getty Images

    Spain has suffered from weather-related production slumps

    Even within Brazil the market is concentrated in the hands of huge industrialised conglomerates.

    In a truly competitive market the price would settle again – but it hasn’t, nor does the industry expect it to. This is a phenomenon that is common to many other ordinary groceries too whose prices have risen.

    Oranges becoming less sweet

    Florida is the other traditional exporter of oranges, but output from the Sunshine State over the past year has been the lowest since the Great Depression, amid a high number of hurricanes and long-term problems caused by citrus greening.

    One problem with greening is that it reduces sugar content, making oranges less sweet.

    “Not many are buying Florida oranges any more unless it is a requirement to label the juice ‘Florida Orange’,” says Maxim McDonald.

    “It’s very difficult to get oranges out of Florida [because of the shortages] and it’s too expensive.”

    VW Pics/Universal Images Group via Getty Images Close up of oranges hanging on a tree with the backdrop of a historic church in the rural town of Carrion de los Cespedes, Seville, Spain
VW Pics/Universal Images Group via Getty Images

    Spain also grows oranges – but Valencia and Seville oranges are mostly exported as fruit, rather than concentrate

    One of the leading suppliers to Tropicana sold off some of its land earlier this year to build homes.

    Tropicana itself, the marquee US brand for orange juice, had to restructure its debts this year. Pepsi has also sold most of its stake in it.

    One of Tropicana’s recent product innovations in the US has been to launch an “essentials” brand of orange juice “blends” – combining orange, apple and pear juice – at a lower price.

    Similar trends can be seen on British shelves. Orange is being mixed with mango, mandarins and clementine juice. Mango purée is especially cheap right now, driven by a good harvest in India. Mandarin concentrate, meanwhile, is cheaper than its orange equivalent because there is less demand for it.

    These developments save money, but also maintain the traditional sweetness of the taste.

    Tariffs: War on the orange

    Then there is the added impact of the recent spike in trade tensions with the US since President Trump introduced new tariffs.

    Oranges, it transpires, have been at the centre of it.

    US exports of orange juice to Canada have slumped to a 20-year low after Canada put counter-tariffs on US exports. The former PM Justin Trudeau warned that Canadians might have to “forgo Florida orange juice”.

    The Trump administration has also settled on a 10% tariff on orange juice coming from Brazil, which will feed into US supermarket prices.

    In 2024, the UK eliminated tariffs on some imports produced from fruit grown outside Britain. But tariffs on certain sweeter, cheaper varieties and blends were not part of this.

    And while the tariff cuts might have helped, they were vastly outweighed by the increase in the underlying price.

    Getty Images US President Donald Trump 
Getty Images

    The Trump administration has put a 10% tariff on orange juice coming from Brazil

    Then there are new regulations around packaging, further adding to the pressures.

    The rules, known as Extended Producer Responsibility, are aimed at improving recycling rates, with a weight-based fee. All juice producers will be impacted, especially those still using glass bottles.

    In August a Bank of England report said that high food price inflation is driven partly – and among other things – by these regulations.

    Did the West fall out of love with OJ?

    In Brazil, the orange harvest has recovered somewhat – this is the greatest hope for a return to normal prices. Yet it coincides with sinking demand: global consumption of orange juice is now down 30% from a peak two decades ago.

    Though this may be partly down to the high prices, in certain parts of the world there has also been a shift in perception about the sugar content and health benefits or otherwise of fruit juice.

    “When young children are not regularly given juice from an early age, they are less likely to be regular juice drinkers in later years,” suggests Philip Coverdale at GlobalData.

    Demand is increasing in countries with growing middle classes, such as China, South Africa, and India. But elsewhere other more exotic fruit juices such as mango, pear and pomegranate are growing in popularity.

    AFP via Getty Images Farm workers spread plant food on the orange trees in the ALG Estates Citrus farm in Citrusdal, South Africa
AFP via Getty Images

    South Africa grows oranges but its supplies are small

    Ultimately, however, orange juice is a staple that supermarkets have long been used to selling at low prices. And the price spikes to £2 a carton could, with for example better weather, simply reverse.

    “The volatility in the harvest appears to have reduced,” says Giles Hurley, UK CEO of Aldi, “Our buying team are doing everything they can to ensure that that saving is passed on to consumers.”

    Others in the supply chain are less convinced, given that much of the frozen concentrate was bought at last year’s high prices. Plus, the stranglehold of the small number of giant producers who control the market remains.

    As for the citrus greening, some major commercial producers, including Coca-Cola, which owns Minute Maid and Innocent, have contributed to a project to Save the Orange, using artificial intelligence to find a way to combat it.

    It’s a long-term project – and even if fruitful, it may be some time before the effect – if at all – filters through to grocery bills.

    But the story of orange prices does also show how an upward price shock gets transmitted around the world far more quickly than a downward one.

    Chocolate, coffee, butter and beef

    Oranges are not the only food that has seen a price spike, of course. The price of beef and veal is up almost 25% in a year. Butter is up almost 19%, and chocolate and coffee 15% and milk over 12%, all according to the Office for National Statistics.

    This all suggests that, more generally, there may be something else at play. And that for all the food and drink spikes, the consumer was actually protected from the worst of it for a period – and now it is pay back time.

    “It might be the retailers didn’t full pass through the cost increase in the first place and therefore it’s a way of recouping some of the margin they would otherwise have got,” says Steve McCorriston, Professor of Agricultural Economics at the University of Exeter.

    EPA - EFE/REX/ Shutterstock A woman shops at a supermarket, facing rows of orange juiceEPA – EFE/REX/ Shutterstock

    Do consumers need to simply accept the fact that the UK will be increasingly exposed to food price shocks?

    Ultimately, though, trying to unpick the precise reason for why our food and drink costs what it does is very difficult – other factors that influence price can go undetected.

    “What we don’t know much about is how these supply chains tend to work in practice. It’s difficult to uncover relationships between retailers and manufacturers or farmers and the use of contracts.”

    There is also a broader question that goes well beyond orange juice: do consumers in the UK need to simply accept the fact that as a densely populated small country with limited agriculture, a changing climate means the UK will be increasingly exposed to food price shocks?

    A 2024 government report on food security noted: “The UK continues to be highly dependent on imports to meet consumer demand for fruit, vegetables and seafood…

    “Many of the countries the UK imports these foods from are subject to their own climate-related challenges and sustainability risks.”

    And so it could be that this is only the start of a wild ride on what we pay for our food and drink.

    Top image credits: Daniel Grizelj/ Tetra Images/ Getty Images

    InDepth notifications banner

    BBC InDepth is the home on the website and app for the best analysis, with fresh perspectives that challenge assumptions and deep reporting on the biggest issues of the day. You can now sign up for notifications that will alert you whenever an InDepth story is published – click here to find out how.

    Continue Reading

  • Holiday optimism and a ‘KPop Demon Hunters’ deal aren’t enough for Mattel’s stock after earnings miss

    Holiday optimism and a ‘KPop Demon Hunters’ deal aren’t enough for Mattel’s stock after earnings miss

    By Bill Peters

    Shoppers have yet to see the full impact of price increases on store shelves, one analyst says

    Mattel reported quarterly results on Tuesday.

    Mattel Inc. on Tuesday said it expects a decent holiday season, but shares still dropped after the toymaker’s third-quarter earnings report missed Wall Street’s expectations.

    The results arrived as toymakers and retailers gear up for the key holiday-shopping stretch – and as they both try to cushion the impact of tariffs, which have made imports more expensive and threatened to push prices higher for inflation-weary consumers.

    For the third quarter, Mattel reported sales of $1.74 billion. That was down 6% year over year, led by a drop in North America, and below FactSet analyst estimates for $1.83 billion. The company’s adjusted earnings per share came in at 89 cents, below forecasts for $1.06.

    Mattel shares (MAT) dropped around 6% in after-hours trading Tuesday.

    Chief Executive Ynon Kreiz said that since the start of the fourth quarter, orders from U.S. retailers had grown as stores try to stock up for the holiday season. So had point-of-sale trends and consumer demand overall.

    “Looking into the balance of the year, we expect a good holiday season for Mattel and strong top-line growth in the fourth quarter,” he said.

    Against that backdrop, Mattel said it was sticking with its full-year outlook. The company expects adjusted earnings per share of $1.54 to $1.66 for the full year.

    Mattel’s results also landed as it tries to become more of a gaming and entertainment company, along with one that sells classic toys like Hot Wheels, Barbie dolls and action figures.

    Netflix Inc. (NFLX) on Tuesday said it was partnering with Mattel and rival Hasbro Inc. (HAS) to roll out toys for “KPop Demon Hunters,” the streaming service’s megahit film. On Monday, Mattel said it had renewed a multiyear licensing agreement to make Disney’s (DIS) Princess and “Frozen” toys.

    Some analysts expect holiday spending to cool slightly this season, as consumers stay selective on purchases and wrestle with tariff-related anxieties. In May, Mattel said it planned to raise prices in the U.S. “where necessary” as it grappled with the Trump administration’s trade wars.

    During Mattel’s earnings call Tuesday, Kreiz said Mattel’s U.S. business during the third quarter was “challenged” by changes in the way retailers are ordering toys that shifted orders to the fourth quarter. More retailers, management said during the call, were opting to let Mattel handle imports and warehousing before taking in items – a more “just-in-time” approach to shipping, as retailers look for more flexibility in committing to orders.

    UBS analyst Arpine Kocharyan said in a research note Monday that Mattel and Hasbro, as larger players in the toy industry, were in better shape than their rivals heading into the holidays. But she noted that the toy companies have largely acknowledged that shoppers have yet to see the full impact of price increases on store shelves.

    Kocharyan said the industry was also running up against issues trying to move production out of China, a country that it has relied on for manufacturing and which the U.S. has targeted in its global trade war.

    “The process of taking production out of China has been bumpier than anticipated for the industry,” she said.

    “Buyers note supply-chain problems and issues with uninterrupted supply, while suppliers highlight disappointing production processes due to a lack of infrastructure in markets such as Vietnam and India and others,” she added.

    -Bill Peters

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

    (END) Dow Jones Newswires

    10-21-25 1942ET

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • Letter: Matcha matchmaking

    Letter: Matcha matchmaking

    In an age of fierce geopolitical tension, it’s easy to lump all Chinese exports into the same category: state-subsidised oversupply flooding western markets.

    However, nothing could be further from the truth when it comes to matcha. As your Big Read shows (“Can Japan satisfy the world’s thirst for matcha?”, October 10), the enormous surge in demand for matcha in the UK and the rest of the world is causing some serious global shortages.

    This trend compelled me to turn to China as a source of supply.

    As a business owner, I found Chinese matcha to be a great commercial delight. I discovered matcha of comparable grade to Japan’s, for half the price, sometimes even less.

    And as a certified tea sommelier, I found Chinese matcha intriguing. Though there was a fair share of pretty rubbish matcha, if one looks there are certainly gems that rival what Japan has to offer. Perhaps not the grand cru of matcha, but premier cru it certainly is.

    So perhaps China turning its hand to this rediscovered agricultural export may end up bringing good to the world — or at least to Gen Z and yuppy millennials, who will no longer have to pay £5 for a cup of matcha.

    Raphael Chow
    Managing Director & Co-founder, Brut Tea, London W1, UK

    Continue Reading

  • Capital One puts credit risk worries to rest, delivers a strong quarter and new buyback

    Capital One puts credit risk worries to rest, delivers a strong quarter and new buyback

    Continue Reading